Yuuwa is a specialist life sciences commercialisation and investment firm based in
Yuuwa was initially established in 2009 as the manager of a $40 million venture capital fund with investment from the Australian Federal Government's Innovation Investment Fund (IIF) program and private investors.
Yuuwa provides expertise to identify new projects and help founders and management start and scale companies in the life sciences area.
Yuuwa connects specialist early stage investors to high quality early stage ventures in life sciences.
LLB BJuris BCom(Hons) GAICD
Liddy has over 20 years as a founder, investor and management in early stage startups. Her prior experience includes co-founder of iCeutica Inc group (acquired), Dimerix Limited (ASX listed) and Argus Biomedical Pty Ltd (acquired). Before working with start-ups Liddy was an Associate Director, Macquarie Bank focusing on mergers and acquisitions. She has been admitted as a barrister and solicitor in various Australian jurisdictions. Liddy is involved in all aspects of investing, building and supporting Yuuwa’s portfolio companies. Liddy serves/has served on the Board of various Yuuwa investee companies including ASX listed AdAlta Limited, Agworld Pty Ltd and Fitgenes Australia Limited. She is a Director of ASX-listed Argenica Ltd (ASX: AGN) and the Ear Science Institute of Australia.
BSc(Hons) PhD MBA GAICD
James is an accomplished scientist, entrepreneur and investor. He has been involved from concept to commercialisation, including CEO, CTO and Board roles, of numerous biotech companies which have resulted in five FDA approved drugs and devices. He conceived the technology behind iCeutica Inc (acquired in 2011) and co-discovered the lead therapy for ASX-listed Dimerix Limited (ASX:DXB), currently in Phase 3 trials for Chronic Kidney Disease.
James is involved in all phases of investment across the Yuuwa portfolio, and is currently a Director of PolyActiva Pty Ltd and alternate Director of Adalta Limited (ASX:1AD). He remains Chairman of Dimerix and is on the Board of the Perron Institute for Neurological and Translational Science.